Bristol Myers, Genentech and Celgene bought their old biotechs. Stafford and co. are ready for their next $60M act
After selling to Genentech, the old Jecure team is back at an RNA-focused startup — and more enthusiastic than ever
858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, Platinum-Resistant Ovarian Cancer Share
858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting
